GO AHEAD. GIVE IT A SHOT.

Join us for a discussion led by members of the hemophilia A community. Hear from panelists Joanna Davis, MD, and Courtney Huckel Carr, RN-BC, MSN, CPNP, and community members* Steven and Olivia as they share why they gave HEMLIBRA a shot.

August 1 • 5:45 PM–7:30 PM EST

What is HEMLIBRA?
HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?
HEMLIBRA increases the potential for your blood to clot. People who use activated prothrombin complex concentrate (aPCC; Feiba®) to treat breakthrough bleeds while taking HEMLIBRA may be at risk of serious side effects related to blood clots.

These serious side effects include:
- Thrombotic microangiopathy (TMA), a condition involving blood clots and injury to small blood vessels that may cause harm to your kidneys, brain, and other organs
- Blood clots (thrombotic events), which may form in blood vessels in your arm, leg, lung, or head

Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. If aPCC (Feiba®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (Feiba®) total.

The most common side effects of HEMLIBRA include:
- injection site reactions (redness, tenderness, warmth, or itching at the site of injection), headache, and joint pain. These are not all of the possible side effects of HEMLIBRA. You can speak with your healthcare provider for more information.

What else should I know about HEMLIBRA?
See the detailed "Instructions for Use" that comes with your HEMLIBRA for information on how to prepare and inject a dose of HEMLIBRA, and how to properly throw away (dispose of) used needles and syringes.
- Stop taking your prophylactic bypassing therapy the day before you start HEMLIBRA
- You may continue taking your prophylactic factor VIII for the first week of HEMLIBRA

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and create an inaccurate result. Speak with your healthcare provider about how this may affect your care.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

Side effects may be reported to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see Important Safety Information, including Serious Side Effects, as well as the HEMLIBRA full Prescribing Information and Medication Guide.

*Panelists and community members have been compensated for their participation.

Unless otherwise noted, Genentech, the sponsor of this industry-sponsored educational symposium, is solely responsible for its content, including any information presented or distributed during the event.

Note: All information disseminated in the Exhibit Hall, as well as content that is presented in the industry-sponsored educational symposia and at company events, are funded by and are the sole responsibility of the exhibitors, sponsors and industry-sponsored educational symposia organizers.

The National Hemophilia Foundation does not endorse particular treatment products or manufacturers; any reference to a product name is not an endorsement by NHF. NHF is not a regulatory agency and cannot make recommendations relating to safety of manufacturing of specific treatment products. For recommendations of a particular product, the regulatory authority in a particular country must make these judgments based on domestic legislation and national health policies.

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The HEMLIBRA logo is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.
The Genentech logo is a registered trademark of Genentech, Inc.
All other trademarks are the property of their respective owners.
©2020 Genentech USA, Inc. All rights reserved. M-US-0000496Rv1.0 08/20